Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). This gene product is also known as granulocyte macrophage colony-stimulating factor receptor. Production is stimulated by granulocyte macrophage colony-stimulating factor (GM-CSF). "A. phagocytophilum" binds to fucosylated and sialylated scaffold proteins on neutrophil and granulocyte surfaces. One notable example is the granulocyte macrophage colony-stimulating factor. Neutropenia indicates a deficiency of neutrophils (the most common granulocyte cell) only. They derive from monocytes, granulocyte stem cells, or the cell division of pre-existing macrophages. Administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) may increase recovery. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. "GEMM" stands for granulocyte, erythrocyte, monocyte, megakaryocyte. Neupogen (filgrastim) is the name for recombinant methionyl human granulocyte colony stimulating factor (r-metHuG-CSF). Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. Filgrastim is a recombinant-DNA form of the naturally occurring granulocyte colony-stimulating factor (G-CSF). GS-ANA are antibodies directed to granulocyte specific nuclear antigens. Plasmapheresis and administration of granulocyte colony-stimulating factor were used to treat the blood abnormalities.